Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea Pharmaceutical Manufacturers Association President Under Fire For Alleged Kickbacks

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Four months after an aggressive declaration that his association would not tolerate any member company involvement in unethical or improper business deals with doctors and hospitals, the president of the Korea Pharmaceutical Manufacturers Association is under fire for his company's alleged kickbacks to doctors

You may also be interested in...



Korean Health Ministry Seeks Prescriptions Listing Active Pharmaceutical Ingredients: Bad News For Brand Name Drugs

SEOUL - South Korea's Ministry of Health, Welfare and Family Affairs is currently mulling plans to require doctors writing prescriptions to include the drug's generic name and active ingredients

Korean Health Ministry Seeks Prescriptions Listing Active Pharmaceutical Ingredients: Bad News For Brand Name Drugs

SEOUL - South Korea's Ministry of Health, Welfare and Family Affairs is currently mulling plans to require doctors writing prescriptions to include the drug's generic name and active ingredients

Korea Moving To Sue 104 Drug Firms, Including Some MNCs, For Selling Substandard Generics

Bioequivalence tests are conducted to compare generic versions of medicines with the originals to ascertain whether or not they are equal. These tests are especially important in South Korea, where generic drugs are the main profit drivers for many local pharmaceutical producers.

Related Content

UsernamePublicRestriction

Register

SC072109

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel